Morgan Stanley Acorda Therapeutics Inc Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.55 - $1.0 $2,527 - $4,596	4,596 Added 92.31%	9,575 $5,000
Q4 2022 Feb 14, 2023	SELL	$0.52 - $0.77 $893 - $1,322	-1,718 Reduced 25.65%	4,979 $3,000
Q3 2022 Nov 14, 2022	BUY	$0.29 - $0.53 $390 - $713	1,346 Added 25.15%	6,697 $1,000
Q2 2022 Oct 27, 2022	BUY	$0.3 - $1.67 $165 - $921	552 Added 11.5%	5,351 $2,000
Q2 2022 Aug 15, 2022	BUY	$0.3 - $1.67 $165 - $921	552 Added 11.5%	5,351 $2,000
Q1 2022 Oct 27, 2022	SELL	$1.61 - $2.5 $888 - $1,380	-552 Reduced 10.32%	4,799 $8,000
Q1 2022 May 13, 2022	SELL	$1.61 - $2.5 $421 - $655	-262 Reduced 5.18%	4,799 $8,000
Q4 2021 Feb 14, 2022	BUY	$2.3 - $4.71 $2,385 - $4,884	1,037 Added 25.77%	5,061 $11,000
Q3 2021 Nov 15, 2021	BUY	$3.36 - $4.79 $13,520 - $19,274	4,024 New	4,024 $19,000

133K

Ticker ACOR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 24,338,400
Market Cap $6.33M
Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.